Monte Rosa's CEO discusses yesterday's data for MRT-2359 in MYC-driven solid tumors

blonca9
Oct 18, 2023
1 min read

Markus Warmuth describes PK/PD and clinical observations the company is seeing for this molecular glue protein degradation approach, how safety is shaping up, and a partnership with Roche.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Monte Rosa's CEO discusses yesterday's data for MRT-2359 in MYC-driven solid tumors

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight